In Jonsson et al. [1] , the relative risks (RRs) of fracture in a population with a T-score at or below a given threshold (e.g. ≤2.5 SD) were estimated as the average for all women at or below the threshold. For greater accuracy, the estimate might consider the average RR of fracture in a population with a T-score at or below the threshold and of the same age as the population in the analysed scenario (e.g. 70-year-old women). We have, therefore, revised the estimate of RRs at or below a T-score threshold. RRs of hip, vertebral, wrist and other fractures at model entry were updated from 2.33, 2.66, 1.46, 1.71 to 3.36, 3.19, 1.60 and 1.92, respectively, for the base case scenario. The proportion of 70-year-old women who are below a given BMD threshold will have a lower mean BMD than the corresponding proportion of all women, which increases the estimated RR of fracture. This consequently favours the comparator with the highest antifracture efficacy in each comparison. Note that the RR estimated at a specific T-score is not affected. The re-estimate affects Tables 4  and 5 
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